Effect of Once-Daily Opicapone on the Pharmacokinetics of Repaglinide
Objective: To evaluate the effect of once-daily administration of opicapone 50 mg on the pharmacokinetics (PK) of repaglinide. Background: Opicapone, a highly selective catechol-O-methyltransferase (COMT)…Impact of repeated oral administration of Opicapone on the plasma pharmacokinetics of levodopa
Objective: To examine the inhibitory effect of COMT on the plasma pharmacokinetics of levodopa resulting from repeated, once daily, oral administration of an Opicapone (OPC)…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Opicapone improves motor and non-motor wearing off symptoms in Parkinson’s disease: an observational real-world study
Objective: To assess the impact of opicapone - a third generation COMT Inhibitor - on motor and non-motor wearing off symptoms in patients suffering from…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…First year of Opicapone for Advanced Parkinson Disease: real-life experience in a single Movement Disorders Unit
Objective: The aim of the study is to evaluate opicapone in an heterogeneous patient population, reflecting daily clinical practice. Background: Opicapone is a new COMT-inhibitor indicated…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to race: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Effect of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Parkinson’s Disease Questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience
Objective: To evaluate the impact of opicapone (OPC) on PDQ-39 in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: OPC, a once-daily COMT…Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: Patient and Clinical Global Impression of Change from the BIPARK-I double-blind experience
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations, the patients’ and clinicians’ perception of PD symptoms improvement [as assessed by…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- Next Page »